Scarica l'app Stockscreener
18.14
1.71%
0.135
Precedente Chiudi:
$18.01
Aprire:
$17.26
Volume 24 ore:
36,391
Relative Volume:
0.28
Capitalizzazione di mercato:
$965.27M
Reddito:
$2.22M
Utile/perdita netta:
$-40.51M
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
$-46.53M
1 W Prestazione:
-29.38%
1M Prestazione:
-29.27%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$17.09
$18.49
Intervallo di 1 settimana:
$17.09
$26.70
Portata 52W:
$17.09
$29.46
Upstream Bio Inc Stock (UPB) Company Profile
Nome
Upstream Bio Inc
Settore
Industria
Telefono
781-208-2466
Indirizzo
890 WINTER STREET, SUITE 200, WALTHAM
Confronta UPB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| UPB | 18.10 | 965.27M | 2.22M | -40.51M | -46.53M | 0.00 |
| VRTX | 447.46 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 742.25 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 591.16 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.73 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.63 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Upstream Bio Inc Borsa (UPB) Ultime notizie
Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
Upstream Bioprocessing Industry Analysis and Forecast, - GlobeNewswire
Upstream Bio, Inc.’s (NASDAQ:UPB) Quiet Period Set To End on November 20th - Defense World
Upstream Bio, Inc.'s (NASDAQ:UPB) Quiet Period Set To End on November 20th - MarketBeat
Brokers Set Expectations for Upstream Bio Q4 Earnings - MarketBeat
Upstream Bio Advances Clinical Trials, Strengthens Financials - TipRanks
Tezspire Phase III Nasal Polyp Data May Lead To Second Indication - Scrip
William Blair Weighs in on Upstream Bio Q4 Earnings - Defense World
Upstream Bio Inc (UPB) Quarterly 10-Q Report - Quartz
Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
FMR LLC Acquires New Stake in Upstream Bio Inc - GuruFocus.com
Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Upstream Bio initiated with an Overweight at Piper Sandler - MSN
Discover the 3 Best-Performing Biotech IPO Stocks of 2024 - MarketBeat
Here are Tuesday's biggest analyst calls: Apple, Microsoft, Palantir, Eli Lilly, Broadcom, Krispy Kreme, Live Nation & more - Head Topics
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say - Benzinga
Upstream Bio initiated with an Overweight at JPMorgan - MSN
This Eaton Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Piper Sandler Begins Coverage on Upstream Bio (NASDAQ:UPB) - MarketBeat
TD Cowen bullish on Upstream Bio, bets on differentiated asthma treatment verekitug - Investing.com
Piper Sandler sees big potential for Upstream Bio asthma therapy, Overweight on stock - Investing.com UK
Upstream Bio prices IPO at $17 per share - MSN
Finance Watch: Septerna Raises $288m In Public Market Debut - Citeline News & Insights
Septerna Shares Jump 19% After IPO Shows Biotech Still Hot - Bloomberg
CeriBell Shares Rise 47% to Lead Trio of Life Sciences IPOs - MSN
Goldman-backed drug developer Septerna raises $288 mln in US IPO - Reuters
Upstream Bio stock rallies 32% following upsized $255M IPO - MSN
Upstream Bioprocessing Market Forecast 2024: Key Global Developments - openPR
Upstream Bio Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Upstream Bio Rings the Opening Bell - Nasdaq
Warren Buffett and Biotech IPOs Highlight Recent Insider Buying - 24/7 Wall St.
Insider Trading Recap: Thursday's Top Buys and Sells in US Stocks - Investing.com
OrbiMed Advisors LLC purchases $14 million in Upstream Bio shares - Investing.com India
Orbimed Advisors LLC Acquires New Stake in Upstream Bio Inc - Yahoo Finance
OrbiMed Advisors LLC purchases $14 million in Upstream Bio shares By Investing.com - Investing.com Nigeria
Upstream bio director Erez Chimovits buys $14 million in shares By Investing.com - Investing.com South Africa
Upstream bio director Erez Chimovits buys $14 million in shares - Investing.com
Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - The Manila Times
Chronic Rhinosinusitis with Nasal Polyps Market Expected - openPR
Upstream Bio and Camp4 and Ceribell Transactions - William Blair
Upstream Bio shares soar in impressive IPO - The Pharma Letter
Opening Day: Another trio of biotech IPOs make Friday debut - Yahoo Finance
HBM portfolio company Upstream Bio raises USD 255 million in successful initial public offering - Marketscreener.com
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - MSN
Upstream Bio Inc Azioni (UPB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Upstream Bio Inc Azioni (UPB) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Oct 15 '24 |
Buy |
17.00 |
825,000 |
14,025,000 |
4,554,873 |
| AI Upstream LLC | 10% Owner |
Oct 15 '24 |
Buy |
17.00 |
1,175,000 |
19,975,000 |
1,175,000 |
0.42%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):